Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KYNU | Q16719 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.57 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.57 |
| ▸ | CASP1 | P29466 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | CTSK | P43235 | 4/20 | 0.52 |
| ▸ | CTSS | P25774 | 3/20 | 0.51 |
| ▸ | CTSL | P07711 | 2/20 | 0.51 |
| ▸ | CTSB | P07858 | 2/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 1/20 | 0.50 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.50 |
| ▸ | MMP13 | P45452 | 2/20 | 0.49 |
| ▸ | TACR1 | P25103 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7564546 | 1.00 | KYNU (0.58) | KYNUCA2GSTP1GSTM2CASP1 | |
| SCHEMBL4968729 | 1.00 | KYNU (0.58) | KYNUCA2GSTP1GSTM2CASP1 | |
| SCHEMBL4973400 | 0.89 | CASP1 (0.62) | CA2CASP1CTSKCTSSCTSL | |
| SCHEMBL6487973 | 0.89 | CASP1 (0.62) | CA2CASP1CTSKCTSSCTSL | |
| SCHEMBL1541597 | 0.89 | CASP1 (0.62) | CA2CASP1CTSKCTSSCTSL | |
| SCHEMBL7810068 | 0.88 | CASP1 (0.61) | CA2CASP1CTSKCTSSCTSL | |
| SCHEMBL7810073 | 0.88 | CASP1 (0.61) | CA2CASP1CTSKCTSSCTSL | |
| SCHEMBL23961328 | 0.88 | KYNU (0.62) | KYNUGSTP1GSTM2ALDH1A1ALOX15 | |
| SCHEMBL6840852 | 0.88 | KYNU (0.62) | KYNUGSTP1GSTM2ALDH1A1ALOX15 | |
| SCHEMBL6840850 | 0.88 | KYNU (0.62) | KYNUGSTP1GSTM2ALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0897911-B9 | PROCESS FOR PRODUCING CYSTEINE DERIVATIVES | KANEKA CORP (JP) | 2004-12-01 | — | — | EP | disclosed |
| EP-0897911-B1 | PROCESS FOR PRODUCING CYSTEINE DERIVATIVES | KANEKA CORP (JP) | 2004-06-09 | — | — | EP | disclosed |
| US-20020169337-A1 | Process for producing optically active cysteine derivatives | KANEKA CORPORATION (JP) | 2002-11-14 | — | — | US | disclosed |
| US-6407281-B1 | ESTERIFICATION WITH ALCOHOL; SOLVENT EXTRACTION | KANEKA CORPORATION (JP) | 2002-06-18 | — | — | US | disclosed |
| EP-1054000-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE CYSTEINE DERIVATIVES | KANEKA CORPORATION (JP) | 2000-11-22 | — | — | EP | disclosed |
| US-6011170-A | SULFIDING A PROTECTED CYSTEINE DERIVATIVE WITH A MERCAPTAN WHEREIN THE REACTION IS CONDUCTED IN THE PRESENCE OF A BASE AND WATER IN AN ORGANIC REACTION SOLVENT. | KANEKA CORPORATION (JP) | 2000-01-04 | — | — | US | disclosed |
| EP-0897911-A1 | PROCESS FOR PRODUCING CYSTEINE DERIVATIVES | KANEKA CORPORATION (JP) | 1999-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169337-A1 | Process for producing optically active cysteine derivatives | LANCL1, ACSL1, ACSL3 | KYNU 660/4885CA2 1421/4885GSTP1 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.